[go: up one dir, main page]

NO20065727L - Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter - Google Patents

Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter

Info

Publication number
NO20065727L
NO20065727L NO20065727A NO20065727A NO20065727L NO 20065727 L NO20065727 L NO 20065727L NO 20065727 A NO20065727 A NO 20065727A NO 20065727 A NO20065727 A NO 20065727A NO 20065727 L NO20065727 L NO 20065727L
Authority
NO
Norway
Prior art keywords
intermediates
arch
synthesis
protein kinase
inhibitors
Prior art date
Application number
NO20065727A
Other languages
English (en)
Norwegian (no)
Inventor
Francois Maltais
Michael R Hale
Qing Tang
Judith Straub
Gabriel Martinez-Botella
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO20065727L publication Critical patent/NO20065727L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
NO20065727A 2004-05-14 2006-12-12 Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter NO20065727L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57130904P 2004-05-14 2004-05-14
PCT/US2005/016902 WO2005113541A1 (fr) 2004-05-14 2005-05-13 Composes pyrroles utilises en tant qu'inhibiteurs de proteines kinases erk, leur synthese, et intermediaires correspondants

Publications (1)

Publication Number Publication Date
NO20065727L true NO20065727L (no) 2006-12-12

Family

ID=35106760

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065727A NO20065727L (no) 2004-05-14 2006-12-12 Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter

Country Status (25)

Country Link
US (6) US7354939B2 (fr)
EP (5) EP3943489A1 (fr)
JP (1) JP5132305B2 (fr)
CN (1) CN1976919A (fr)
AR (2) AR051735A1 (fr)
AU (1) AU2005245885B2 (fr)
BR (1) BRPI0511111A (fr)
CA (1) CA2566461C (fr)
CY (1) CY1122336T1 (fr)
DK (1) DK3305776T3 (fr)
ES (4) ES2751761T3 (fr)
HU (1) HUE047130T2 (fr)
IL (1) IL179207A0 (fr)
LT (1) LT3305776T (fr)
MX (1) MXPA06013209A (fr)
NO (1) NO20065727L (fr)
NZ (1) NZ551582A (fr)
PL (1) PL3305776T3 (fr)
PT (1) PT3305776T (fr)
RU (1) RU2376299C2 (fr)
SI (1) SI3305776T1 (fr)
TW (1) TW200607803A (fr)
UA (1) UA84930C2 (fr)
WO (1) WO2005113541A1 (fr)
ZA (1) ZA200609975B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1606284B1 (fr) * 2003-03-13 2009-12-02 Vertex Pharmaceuticals Incorporated Compositions utiles en tant qu'inhibiteurs de proteine kinases
WO2005100342A1 (fr) * 2004-03-26 2005-10-27 Vertex Pharmaceuticals, Incorporated Inhibiteurs de erk2 a base de pyridine et utilisation de ceux-ci
ES2751761T3 (es) * 2004-05-14 2020-04-01 Vertex Pharma Compuestos de pirrol como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
KR20080103996A (ko) * 2006-02-16 2008-11-28 쉐링 코포레이션 Ｅｒｋ 억제제로서 피롤리딘 유도체
PE20090326A1 (es) * 2007-06-05 2009-04-04 Schering Corp Compuestos heterociclos como inhibidores de erk
CN102015693B (zh) 2008-02-21 2014-10-29 默沙东公司 作为erk抑制剂的化合物
CN102146074B (zh) * 2011-01-26 2013-02-06 江苏先声药物研究有限公司 吡咯衍生物的制备方法及应用
WO2012172093A1 (fr) 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dérivé de dihydroindolizine à titre de modulateurs des récepteurs métabotropes de glutamate
HUE056551T2 (hu) 2013-10-14 2022-02-28 Univ Indiana Res & Tech Corp Az akamprozát alkalmazása az ERK 1-2 aktiváció modulálására az FXS és az ASD állati modelljeiben, valamint az FXS és ASD diagnózissal rendelkezõ egyéneken
EP3061754A4 (fr) 2013-10-23 2017-03-22 Takeda Pharmaceutical Company Limited Composé hétérocyclique
WO2015095833A1 (fr) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Traitement de cancers hématologiques
JP6678584B2 (ja) * 2013-12-20 2020-04-22 バイオメッド バレー ディスカバリーズ，インコーポレイティド Ｃｄｋ阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがん処置
WO2015095838A2 (fr) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Traitements du cancer faisant appel à des associations d'inhibiteurs de l'erk et de la mek de type 1
JP6678583B2 (ja) * 2013-12-20 2020-04-22 バイオメッド バレー ディスカバリーズ，インコーポレイティド ２型ｍｅｋ阻害剤およびｅｒｋ阻害剤の組み合わせを用いるがん処置
EP3082957B1 (fr) * 2013-12-20 2022-04-06 Biomed Valley Discoveries, Inc. Traitements du cancer utilisant des combinaisons des inhibiteurs de la voie pi3k/akt et de l'erk
WO2015095835A1 (fr) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Méthodes de modulation de la prise d'iode radioactif pour le traitement de cancers réfractaires à l'iode radioactif
WO2015095842A2 (fr) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Méthodes et compositions pour le traitement de cancers résistants aux inhibiteurs de la voie mapk non erk
WO2015095807A1 (fr) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Traitements du cancer au moyen de combinaisons d'inhibiteurs de l'egfr et de l'erk
WO2015095831A1 (fr) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Traitements du cancer faisant appel à des associations d'inhibiteurs de l'erk et de la mtor
MX384721B (es) * 2013-12-20 2025-03-14 Biomed Valley Discoveries Inc Tratamiento del cáncer usando combinaciones de inhibidores de erk y raf.
NZ772411A (en) * 2015-01-30 2022-05-27 Vertex Pharma Crystalline forms of c21h22ci2n4o2
CA2975116C (fr) * 2015-01-30 2022-10-11 Biomed Valley Discoveries, Inc. Malonate cristallin c21h22c12n4o2
WO2016187028A1 (fr) * 2015-05-15 2016-11-24 Celgene Avilomics Research, Inc. Composés hétéroaryles, leur synthèse, et intermédiaires de ceux-ci
WO2016192063A1 (fr) * 2015-06-03 2016-12-08 Changzhou Jiekai Pharmatech Co. Ltd Composés hétérocycliques utilisés comme inhibiteurs d'erk
WO2016192064A1 (fr) 2015-06-03 2016-12-08 Js Innopharm (Shanghai) Ltd. Composés hétérocycliques pour le traitement du psoriasis
SI3365334T1 (sl) 2015-10-21 2024-10-30 Otsuka Pharmaceutical Co., Ltd. Spojine benzolaktama kot zaviralci protein kinaze
EP3170822A1 (fr) 2015-11-18 2017-05-24 AGV Discovery Dérivés d'azaindole et leur utilisation en tant qu'inhibiteurs de kinase erk
US10934304B2 (en) 2016-10-05 2021-03-02 Recurium Ip Holdings, Llc Spirocyclic compounds
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
WO2019073435A1 (fr) * 2017-10-12 2019-04-18 Novartis Ag Combinaisons d'inhibiteurs de mdm2 avec des inhibiteurs d'erk pour traiter des cancers
WO2019180141A1 (fr) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinaisons de rogaratinib
WO2020223177A1 (fr) * 2019-04-29 2020-11-05 The Board Of Trustees Of The University Of Illinois Inhibiteurs de mek pour la cicatrisation de la cornée et la néovascularisation
WO2021020841A1 (fr) * 2019-07-29 2021-02-04 Standigm Inc. Composition pour la prévention ou le traitement d'une maladie hépatique métabolique
EP4212531A1 (fr) 2022-01-14 2023-07-19 AGV Discovery Dérivés d'azaindole et leur utilisation en tant qu'inhibiteurs de kinase erk
CN118765276A (zh) * 2022-03-08 2024-10-11 甘李药业股份有限公司 氘代化合物，及其制备方法和应用
JP2025509969A (ja) * 2022-03-24 2025-04-11 バイオメッド バレー ディスカバリーズ，インコーポレイティド Ｅｒｋのピロール阻害剤の重水素化アナログ、その合成およびその中間体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5565413A (en) * 1994-12-06 1996-10-15 Zeneca Limited Substituted pyridyl phenyl ketone herbicides
US5472966A (en) * 1995-03-29 1995-12-05 Bristol-Myers Squibb Company Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
WO2000069847A1 (fr) * 1999-05-14 2000-11-23 Ortho-Mcneil Pharmaceutical, Inc. 3-pyridyle-4-arylpyrroles substitues et methodes prophylactiques et therapeutiques associees
DE60027718T2 (de) 1999-06-22 2007-05-16 Takeda Pharmaceutical Co. Ltd. Acylhydrazinderivate, verfahren zu ihrer herstellung und ihre verwendung
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
EP1506189A1 (fr) * 2002-04-26 2005-02-16 Vertex Pharmaceuticals Incorporated Derives de pyrrole utilises en tant qu'inhibiteurs de erk2 et leurs utilisations
EP1554269A1 (fr) * 2002-07-09 2005-07-20 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles et thiazoles presentant des activites d'inhibition des proteines kinases
ES2575522T3 (es) * 2002-07-18 2016-06-29 Janssen Pharmaceutica Nv Inhibidores de quinasas con triazina sustituida
GB0217780D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
EP1546117A2 (fr) * 2002-08-14 2005-06-29 Vertex Pharmaceuticals Incorporated Inhibiteurs de la proteine kinase et leurs utilisations
EP1606284B1 (fr) * 2003-03-13 2009-12-02 Vertex Pharmaceuticals Incorporated Compositions utiles en tant qu'inhibiteurs de proteine kinases
ES2751761T3 (es) * 2004-05-14 2020-04-01 Vertex Pharma Compuestos de pirrol como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos

Also Published As

Publication number Publication date
CN1976919A (zh) 2007-06-06
HUE047130T2 (hu) 2020-04-28
ES2897422T3 (es) 2022-03-01
EP3943489A1 (fr) 2022-01-26
USRE46097E1 (en) 2016-08-09
SI3305776T1 (sl) 2020-01-31
AR051735A1 (es) 2007-02-07
DK3305776T3 (da) 2019-12-09
EP3305776A1 (fr) 2018-04-11
ES2651439T3 (es) 2018-01-26
EP3608315B1 (fr) 2021-08-11
CA2566461C (fr) 2012-07-10
ES2513965T3 (es) 2014-10-27
EP1753738A1 (fr) 2007-02-21
LT3305776T (lt) 2020-01-10
AU2005245885B2 (en) 2011-01-20
CA2566461A1 (fr) 2005-12-01
US7354939B2 (en) 2008-04-08
USRE49500E1 (en) 2023-04-25
AR106755A2 (es) 2018-02-14
HK1203505A1 (en) 2015-10-30
ZA200609975B (en) 2008-02-27
USRE48266E1 (en) 2020-10-20
EP3305776B1 (fr) 2019-09-25
TW200607803A (en) 2006-03-01
RU2006144445A (ru) 2008-06-20
EP3608315A1 (fr) 2020-02-12
PT3305776T (pt) 2019-12-17
EP2799434A1 (fr) 2014-11-05
NZ551582A (en) 2011-01-28
WO2005113541A1 (fr) 2005-12-01
IL179207A0 (en) 2007-03-08
JP2007537295A (ja) 2007-12-20
US20060106069A1 (en) 2006-05-18
JP5132305B2 (ja) 2013-01-30
MXPA06013209A (es) 2007-01-16
RU2376299C2 (ru) 2009-12-20
US20230183276A1 (en) 2023-06-15
USRE47318E1 (en) 2019-03-26
HK1247910A1 (en) 2018-10-05
EP2799434B1 (fr) 2017-08-02
PL3305776T3 (pl) 2020-03-31
BRPI0511111A (pt) 2007-11-27
ES2751761T3 (es) 2020-04-01
AU2005245885A1 (en) 2005-12-01
EP1753738B1 (fr) 2014-07-09
UA84930C2 (ru) 2008-12-10
CY1122336T1 (el) 2021-01-27

Similar Documents

Publication Publication Date Title
NO20065727L (no) Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20084435L (no) C-MET proteinkinaseinhibitorer
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
NO20092130L (no) Tricykliske heteroarylforbindelser anvendelige som inhibitorer of januskinase
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20083918L (no) Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
NO20072795L (no) Pyrazol [1,5-a]pyrimidiner som er nyttige som inhibitorer av proteinkinaser
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
DE602006021776D1 (de) Als kinaseinhibitoren geeignete aminopyrimidine
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
NO20070502L (no) Azaindoler nyttige som inhibitorer av proteinkinaser
NO20080967L (no) Benzimidazoler nyttige som inhibitorer av proteinkinaser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application